<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of malaria infection in travelers</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of malaria infection in travelers</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of malaria infection in travelers</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathrine R Tan, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Johanna Daily, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Malaria is an important cause of fever and serious illness in returned travelers [<a href="#rid1">1,2</a>]. Among nearly 7000 returned travelers with fever seen at a GeoSentinel clinic between 1997 and 2006, for example, malaria was the most common specific etiologic diagnosis, found in 21 percent of cases [<a href="#rid1">1</a>]. The relative risk of malaria is higher among returned travelers from sub-Saharan Africa than those from Asia or the Americas [<a href="#rid3">3</a>].</p><p>There were 2161 cases of malaria reported in 2017 to the United States Centers for Disease Control and Prevention (CDC) [<a href="#rid3">3</a>]. More than half of the reported cases are due to <em>Plasmodium falciparum</em>, which causes the most severe disease; patients with <em>P. falciparum</em> may progress to life-threatening illness within hours [<a href="#rid4">4,5</a>]. Since 2011, there has been an average of seven malaria deaths per year in the United States.</p><p>Prevention efforts should be aimed at all forms of malaria. In addition to <em>P. falciparum</em>, other <em>Plasmodium</em> species that cause human malaria include <em>P. vivax</em>, <em>P. ovale</em>, <em>P. malariae</em>, and <em>P. knowlesi</em>. While <em>P. falciparum</em> is most likely to result in severe disease, all malaria species can cause severe disease and death [<a href="#rid6">6,7</a>]. In general, most chemoprophylaxis regimens are designed to prevent primary attacks of malaria. <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> and <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> can also prevent relapses of malaria caused by <em>P. vivax</em> and <em>P. ovale</em>. (See <a class="local">'Drug mechanisms'</a> below and <a class="local">'Primaquine'</a> below and <a class="local">'Tafenoquine'</a> below.)</p><p>Most travelers who develop malaria do so because they do not adhere to an effective chemoprophylactic drug regimen [<a href="#rid8">8-10</a>]. In addition, many travelers frequently fail to use personal protection measures for mosquito bite prevention.</p><p>Issues related to risk assessment, counseling, mosquito bite prevention, and antimalarial chemoprophylaxis for prevention of malaria will be reviewed here. The clinical manifestations, diagnosis, and treatment of malaria are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5709.html" rel="external">"Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children"</a> and  <a class="medical medical_review" href="/z/d/html/5707.html" rel="external">"Laboratory tools for diagnosis of malaria"</a> and  <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">"Treatment of severe malaria"</a> and  <a class="medical medical_review" href="/z/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children"</a>.)</p><p>The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.</p><p class="headingAnchor" id="H2"><span class="h1">RISK ASSESSMENT</span><span class="headingEndMark"> — </span>The risk of malaria transmission depends on a variety of factors including the geographic region visited and the type of traveler [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Destination</span><span class="headingEndMark"> — </span>In addition to the geographic region visited, the risk of malaria transmission depends upon the type of accommodation (eg, open air, tented, air conditioned, or screened), the season (rainy versus dry), the elevation, and the duration of exposure.</p><p>Geographic risk assessment for malaria requires a detailed review of the planned itinerary together with the most recent United States Centers for Disease Control and Prevention (CDC) guidelines and advisories [<a href="#rid12">12</a>]. Listings of regions where malaria transmission occurs, the presence of antimalarial drug resistance, and recommended chemoprophylaxis for specific destination are available in the CDC publication "Health Information for International Travel" (also known as the Yellow Book), which may be accessed online [<a href="#rid13">13</a>]. The World Health Organization (WHO) provides useful online information including maps and malaria data [<a href="#rid14">14</a>].</p><p>An excellent summary of areas where malaria transmission occurs and prophylaxis by country is available on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmalaria%2Ftravelers%2Fcountry_table%2Fa.html&amp;token=ayNIhhJaRWBBmPhCXLAzhqsK3fLivjA6n0EN1A%2BjbJdUkPN%2BLu4BTZKL%2Bkj5I9nCDMY8L%2Bro6MGpyyceiVTsHQ%3D%3D&amp;TOPIC_ID=5722" target="_blank">CDC website</a>. </p><p class="headingAnchor" id="H4"><span class="h2">Type of traveler</span><span class="headingEndMark"> — </span>Important risk groups include travelers born in regions with endemic malaria who relocate outside the endemic area but subsequently return to visit friends and relatives (known as VFRs), pregnant patients, and military personnel.</p><p>VFR travelers are at greatest risk for malaria infection; this group includes individuals born in regions with endemic malaria who have emigrated outside these regions, as well as the subsequent generation of children born outside endemic areas [<a href="#rid15">15-17</a>]. VFRs pose unique challenges for malaria prevention since those with acquired immunity afforded some degree of protection against malaria while they resided in the endemic area, although such immunity wanes outside endemic regions [<a href="#rid18">18</a>]. In addition, such individuals may have difficulty seeking or accessing preventive services, may receive incorrect information regarding appropriate prophylaxis measures, and may not appreciate the risk or severity of infection once their immunity has waned [<a href="#rid15">15</a>]. Among patients for whom reason for travel was known, 70 percent of the severe cases of imported malaria in 2015 (including all five deaths) were in VFRs [<a href="#rid3">3</a>].</p><p>Pregnant travelers should be advised to defer travel until after delivery whenever feasible. (See <a class="local">'Pregnant patients'</a> below.)</p><p>Military personnel represent another important risk group; these individuals may have inadequate protection from mosquito bites given prolonged periods of night-time exposure to biting <em>Anopheles</em> mosquitoes with accommodations that have inadequate screens or bednets [<a href="#rid19">19</a>].</p><p>Human immunodeficiency virus (HIV)-infected travelers warrant the same approach to prevention of malaria as HIV-uninfected travelers. Potential drug interactions should be considered. (See <a class="local">'Drug interactions'</a> below.)</p><p class="headingAnchor" id="H237142218"><span class="h1">TOOLS FOR PREVENTION</span></p><p class="headingAnchor" id="H5"><span class="h2">Counseling</span><span class="headingEndMark"> — </span>Travelers to malarious areas should understand that their planned itinerary puts them at risk for malaria, a serious infection that can be fatal after just several days of illness [<a href="#rid20">20</a>]. Prevention measures include avoiding mosquito bites and adhering to antimalarial chemoprophylaxis. However, travelers should also understand that no chemoprophylaxis regimen guarantees complete protection and that fever during or after travel is a medical emergency requiring urgent medical attention [<a href="#rid21">21</a>]. Other symptoms may include headache, myalgia, cough, nausea, abdominal pain, vomiting, and diarrhea. (See  <a class="medical medical_review" href="/z/d/html/5709.html" rel="external">"Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children"</a>.)</p><p>Travelers should be counseled that their travel history is an important clue to bring to the attention of the health care provider in the case of illness during the first year following exposure [<a href="#rid21">21</a>]. Because most chemoprophylactic agents (with the exception of <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> and <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a>) do not eradicate the dormant hypnozoites of <em>P. vivax</em> and <em>P. ovale</em> capable of causing relapsing malaria, infection with these species may present months following exposure in spite of full adherence to chemoprophylaxis [<a href="#rid21">21</a>]. (See <a class="local">'Drug mechanisms'</a> below and <a class="local">'Primaquine'</a> below and <a class="local">'Tafenoquine'</a> below.) </p><p>In semi-immune individuals born in endemic areas, <em>P. falciparum</em> may present years after their last period of exposure [<a href="#rid22">22</a>].</p><p>Travelers planning prolonged visits to endemic areas should continue prophylaxis throughout their stay and for the recommended period of time afterward. Local laboratories in developing regions may have high rates of false-positive malaria diagnoses; travelers who become ill should be advised to seek expert advice concerning malaria diagnosis and therapy [<a href="#rid23">23-25</a>]. In such cases, the chemoprophylactic regimen should be continued together with treatment offered locally, unless there are significant drug-drug interactions (such as <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> with halofantrine). If the initial evaluation demonstrates negative blood films, thick and thin blood films or rapid diagnostics should be repeated twice (12 to 24 hours apart).</p><p>Pregnant patients are an important risk group, as malaria can be a life-threatening infection for both mother and fetus [<a href="#rid26">26</a>]. Risk of stillbirth, spontaneous abortion, and other adverse pregnancy outcomes are increased in the setting of malaria; pregnant patients should be advised to defer travel until after delivery whenever feasible. (See <a class="local">'Pregnant patients'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h2">Mosquito bite prevention</span><span class="headingEndMark"> — </span>Travelers to malarious areas should receive instructions regarding methods to prevent bites from <em>Anopheles</em> mosquitoes; such measures also help reduce bites from sandflies, ticks, and other mosquito species. These include [<a href="#rid27">27-29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding outdoor exposure between dusk and dawn (when <em>Anopheles</em> mosquitoes feed)</p><p class="bulletIndent1"><span class="glyph">●</span>Wearing clothing that reduces the amount of exposed skin</p><p class="bulletIndent1"><span class="glyph">●</span>Wearing insect repellant</p><p class="bulletIndent1"><span class="glyph">●</span>Sleeping within bed nets treated with insecticide (eg, <a class="drug drug_general" data-topicid="9759" href="/z/d/drug information/9759.html" rel="external">permethrin</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Staying in well-screened or air-conditioned rooms</p><p></p><p>Insect repellents recommended by the United States Centers for Disease Control and Prevention for reducing the risk of malaria include N,N-diethyl-m-toluamide (DEET), picaridin, ethyl butylacetylaminopropionate (IR3535), and oil of lemon eucalyptus (OLE) [<a href="#rid13">13,28</a>]. (See  <a class="medical medical_review" href="/z/d/html/4085.html" rel="external">"Prevention of arthropod and insect bites: Repellents and other measures"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>DEET (30 to 50%) is generally protective for at least four hours, although lower percentage preparations provide a shorter duration of protection. When used as directed, this same concentration of DEET is safe for infants and children &gt;2 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Picaridin is a synthetic repellant. This agent (20% concentration) and DEET (35% concentration) have comparable efficacy for protection against malaria vectors up to eight hours after application [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IR3535 (15% or higher) is protective for about eight hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>OLE in products registered with the Environmental Protection Agency is an effective repellant and can be used in children &gt;3 years. "Pure" eucalyptus oil (essential oil) has not been tested for efficacy or safety.</p><p></p><p>In addition to applying insect repellants to the skin, fabric may be treated with <a class="drug drug_general" data-topicid="9759" href="/z/d/drug information/9759.html" rel="external">permethrin</a> or other residual insecticides [<a href="#rid27">27,29,31,32</a>]. Permethrin is a synthetic compound that causes nervous system toxicity to insects with low toxicity for humans [<a href="#rid33">33</a>]. It is available in outdoor supply stores as an aerosol clothing spray (eg, Permanone Repellent).</p><p>Clothing and bed netting treated with <a class="drug drug_general" data-topicid="9759" href="/z/d/drug information/9759.html" rel="external">permethrin</a> effectively repel mosquitoes for more than one week even with washing and field use [<a href="#rid27">27,29</a>]. Standard nets dipped in permethrin are effective for three washes, whereas newer formulations can withstand 20 washes. Long-lasting insecticide impregnated nets (LLINs) can remain effective as long as three years. Since use of such nets is very effective for reducing the risk of malaria, travelers to endemic areas with accommodations lacking screens or air conditioning (such as travelers visiting friends and relatives or backpackers) should sleep under insecticide-treated nets [<a href="#rid29">29</a>]. It is advisable to bring netting as local availability may be unpredictable.</p><p class="headingAnchor" id="H7"><span class="h2">Chemoprophylaxis</span><span class="headingEndMark"> — </span>Individual itineraries should be reviewed together with the most recent guidelines and advisories to determine the appropriate approach to chemoprophylaxis  (<a class="graphic graphic_figure graphicRef103385" href="/z/d/graphic/103385.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef72797" href="/z/d/graphic/72797.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef142995" href="/z/d/graphic/142995.html" rel="external">figure 3</a>) [<a href="#rid12">12,13</a>].</p><p>Listings of regions where malaria transmission occurs, the presence of antimalarial drug resistance, and recommended chemoprophylaxis for specific destination are available in the United States Centers for Disease Control and Prevention (CDC) publication "Health Information for International Travel" (also known as the Yellow Book). Additional information is available on the CDC's malaria <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmalaria%2Ftravelers%2Fcountry_table%2Fa.html&amp;token=ayNIhhJaRWBBmPhCXLAzhqsK3fLivjA6n0EN1A%2BjbJdUkPN%2BLu4BTZKL%2Bkj5I9nCDMY8L%2Bro6MGpyyceiVTsHQ%3D%3D&amp;TOPIC_ID=5722" target="_blank">website</a> [<a href="#rid13">13</a>]. The World Health Organization (WHO) provides useful online information including maps and malaria data [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H2156799266"><span class="h3">Suggested approach</span><span class="headingEndMark"> — </span>Selection of chemoprophylaxis must be tailored to individual itineraries and circumstances. For patients traveling to several destinations with different malaria transmission patterns, it may be simplest to select a single agent that will be effective for the entire duration of exposure.</p><p class="bulletIndent1"><span class="glyph">●</span>For travelers to destinations where malaria cases occur only sporadically and risk to travelers is very low, mosquito avoidance measures should be used; no chemoprophylaxis is needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For travelers at risk of malaria infection in destinations where chloroquine-resistant <em>P. falciparum</em> malaria is present, mosquito avoidance measures should be used in conjunction with chemoprophylaxis. Options for chemoprophylaxis include <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a>, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, and <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a>; all four agents are highly efficacious for prevention of malaria. Comparative studies among travelers taking mefloquine or atovaquone-proguanil have demonstrated that fewer side effects are experienced among recipients of atovaquone-proguanil, although this agent is more costly [<a href="#rid34">34</a>]. Short-term travelers may prefer the shorter course of atovaquone-proguanil, whereas long-term travelers may prefer the convenience of weekly mefloquine. Doxycycline must be taken daily and may cause sun sensitization. Travelers must be tested for G6PD deficiency before using tafenoquine. (See <a class="local">'Tafenoquine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For travelers at risk of malaria infection in the very few destinations in the world where chloroquine-sensitive <em>P. falciparum</em> malaria is present, mosquito avoidance measures should be used in conjunction with chemoprophylaxis. <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> may be used, although short-term travelers may prefer the shorter course of <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a>. <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">Mefloquine</a> and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> are also effective agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For travelers at risk of malaria infection in destinations where <em>P. falciparum</em> strains resistant to <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> and <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> are present (such as in the malaria-endemic regions of Thailand bordering Myanmar [Burma] and Cambodia [eg, eastern provinces of Myanmar (Burma) and western provinces of Cambodia], China, Laos, and Vietnam), mosquito avoidance measures should be used in conjunction with chemoprophylaxis. Options include <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For travelers at risk of malaria infection in destinations where the predominant species is <em>P. vivax</em> (such as the malaria-endemic parts of Mexico and Central America), mosquito avoidance measures should be used in conjunction with chemoprophylaxis. <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> may be used in the absence of glucose-6-phosphate dehydrogenase (G6PD) deficiency; <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> is also effective. Short-term travelers may prefer the shorter course of <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a> or tafenoquine. <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">Mefloquine</a> and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> are also effective agents [<a href="#rid35">35</a>].</p><p></p><p>It is appropriate to administer antimalarial drugs for as long as needed for prevention of malaria infection; there is no evidence of toxicity after prolonged use. Evidence supports long-term use of <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a>, <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, and <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> for up to two years [<a href="#rid36">36,37</a>]. Beyond two years, data are more limited. For those staying in a malaria-endemic country for extended (&gt;6 months) period of time, it will be important to identify local health resources for the timely diagnosis and treatment of malaria.</p><p>Antimalarial therapy should be started prior to travel, continued regularly during exposure, and for a period of time following departure from the endemic area  (<a class="graphic graphic_table graphicRef75761" href="/z/d/graphic/75761.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef54777" href="/z/d/graphic/54777.html" rel="external">table 2</a>) [<a href="#rid38">38</a>]. A prescription for the full supply of medication should be written and filled prior to departure; the sale of counterfeit and poor quality antimalarials is an increasing problem in Asia and Africa [<a href="#rid39">39,40</a>]. Travelers should understand the importance of careful adherence to the chemoprophylaxis regimen, even though no chemoprophylaxis regimen guarantees complete protection. Individual agents are discussed in detail in the following section  (<a class="graphic graphic_table graphicRef75761" href="/z/d/graphic/75761.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H10"><span class="h3">Drug regimens</span><span class="headingEndMark"> — </span>Chemoprophylaxis agents vary with respect to cost, adverse effects, and dosing schedule [<a href="#rid41">41</a>]. Reviewing these items during the travel visit is important for facilitating adherence. Availability of the drugs, as well as recommendations for their use, may vary depending on the country of origin.</p><p class="headingAnchor" id="H11"><span class="h4">Atovaquone-proguanil</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> acts synergistically with proguanil against chloroquine-sensitive and chloroquine-resistant <em>P. falciparum</em>, as well as the other malaria species that cause human malaria [<a href="#rid42">42</a>]. The efficacy of <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a> is equivalent to that of <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> [<a href="#rid43">43</a>]. Atovaquone-proguanil does not prevent hypnozoite formation by <em>P. vivax </em>or <em>P. ovale</em>; in areas with high rates of infection due to these species, presumptive antirelapse therapy with <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> may be necessary to prevent relapse for persons who had been to those areas for extended periods of time. (See <a class="local">'Drug mechanisms'</a> below and <a class="local">'Primaquine'</a> below and <a class="local">'Tafenoquine'</a> below.)</p><p><a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">Atovaquone-proguanil</a> is administered daily with food beginning one to two days prior to exposure, during exposure, and for one week following exposure [<a href="#rid44">44-46</a>]. Shorter courses are not recommended [<a href="#rid47">47</a>]. Dosing is outlined in the tables  (<a class="graphic graphic_table graphicRef75761" href="/z/d/graphic/75761.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef54777" href="/z/d/graphic/54777.html" rel="external">table 2</a>). The drug is well tolerated, with excellent profiles of safety and efficacy [<a href="#rid34">34,42,43,48-54</a>]. Adverse effects may include gastrointestinal upset, insomnia, headache, rash, and mouth ulcers [<a href="#rid48">48,55</a>].</p><p><a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">Atovaquone-proguanil</a> is contraindicated in patients with creatinine clearance &lt;30 mL per minute, and it is not recommended for use in pregnant patients, infants weighing &lt;5 kg, or women breastfeeding infants weighing &lt;5 kg due to insufficient safety data.</p><p class="headingAnchor" id="H1288391729"><span class="h4">Chloroquine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> may be used for prophylaxis for individuals traveling to malarious areas without chloroquine resistance  (<a class="graphic graphic_figure graphicRef103385" href="/z/d/graphic/103385.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef72797" href="/z/d/graphic/72797.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef142995" href="/z/d/graphic/142995.html" rel="external">figure 3</a>) (see <a class="local">'Drug resistance'</a> below). Chloroquine has activity against all plasmodial species causing human malaria with the exception of chloroquine-resistant <em>P. falciparum</em> strains and uncommon strains of <em>P. vivax</em> in Oceania and Asia. In addition, chloroquine does not prevent the development of hypnozoites, the dormant forms of <em>P. vivax</em> or <em>P. ovale</em> malaria. Thus, for those with extended exposure to areas with high rates of infection due to these species, presumptive antirelapse therapy with <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> may be necessary to prevent relapse. (See <a class="local">'Drug mechanisms'</a> below and <a class="local">'Primaquine'</a> below and <a class="local">'Tafenoquine'</a> below.)</p><p>Formulations include <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> phosphate and <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>  (<a class="graphic graphic_table graphicRef75761" href="/z/d/graphic/75761.html" rel="external">table 1</a>) [<a href="#rid13">13</a>]. Chloroquine is administered once weekly starting one week prior to exposure, once weekly while in the malaria endemic area, and then once weekly for four weeks following exposure. Dosing is outlined in the tables  (<a class="graphic graphic_table graphicRef75761" href="/z/d/graphic/75761.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef54777" href="/z/d/graphic/54777.html" rel="external">table 2</a>).</p><p>Apart from its bitter taste, <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> is usually well tolerated. Minor side effects include gastrointestinal disturbances, dizziness, blurred vision, and headache; gastrointestinal problems may be alleviated by taking the drug with food. It has been associated with flares of psoriasis and pruritus, although serious side effects are rare [<a href="#rid56">56</a>]. The mechanism of pruritus is not entirely clear, but it appears to be a side effect of the medicine, not an allergic reaction. Retinal injury, which can occur when high doses of chloroquine are used to treat rheumatoid arthritis, does not occur with the weekly doses used for malaria prevention [<a href="#rid57">57</a>]. Chloroquine is safe for use in pregnancy and while breastfeeding.</p><p class="headingAnchor" id="H13"><span class="h4">Doxycycline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> has activity against chloroquine-sensitive and chloroquine-resistant <em>P. falciparum</em>, as well as the other malaria species that cause human malaria [<a href="#rid13">13,58-60</a>]. Comparative trials have demonstrated equivalent efficacy of doxycycline with <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> (eg, 93 to 99 percent) [<a href="#rid59">59,61-63</a>]. Doxycycline can provide some protection against infection with some rickettsial infections (eg, scrub typhus) and <em>Leptospira</em> spp [<a href="#rid64">64,65</a>]. However, doxycycline does not prevent the development of the hypnozoites of <em>P. vivax</em> or <em>P. ovale </em>malaria. Thus, for those with extended exposure to areas with high rates of infection due to these species, presumptive antirelapse therapy with <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> may be necessary to prevent relapse. (See <a class="local">'Drug mechanisms'</a> below and <a class="local">'Primaquine'</a> below.)</p><p><a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> is administered daily beginning one to two days prior to exposure, daily during exposure, and daily for four weeks following exposure. Dosing is outlined in the tables  (<a class="graphic graphic_table graphicRef75761" href="/z/d/graphic/75761.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef54777" href="/z/d/graphic/54777.html" rel="external">table 2</a>). Noncompliance (even for a few days) with this daily regimen is an important reason for doxycycline prophylaxis failure [<a href="#rid48">48,66</a>].</p><p><a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> is usually well tolerated but has been associated with gastrointestinal upset; less commonly, ultraviolet photosensitivity, <em>Candida</em> vaginitis, and rare cases of esophageal ulceration may also occur [<a href="#rid67">67-69</a>]. The drug should be taken with fluids and food; it should not be administered immediately before lying down. Sunscreen should be applied liberally (before insect repellent) for the duration of prophylaxis. It is advisable to offer women antifungal self-treatment for management of <em>Candida</em> vaginitis (eg, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>). Doxycycline is contraindicated in pregnant and breastfeeding women and for malaria prophylaxis in children &lt;8 years of age.</p><p class="headingAnchor" id="H3742193077"><span class="h4">Mefloquine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">Mefloquine</a> is effective for prevention of malaria due to chloroquine-sensitive and chloroquine-resistant <em>P. falciparum</em>, as well as the other malaria species that cause human malaria [<a href="#rid70">70</a>]. In a study of almost 140,000 travelers to East Africa, the prophylactic efficacy of mefloquine was 91 percent [<a href="#rid71">71,72</a>].</p><p><a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">Mefloquine</a> is not effective for prevention of malaria due to mefloquine-resistant <em>P. falciparum</em>, which is found along the Thailand-Cambodian border region and parts of China, Myanmar (Burma), Vietnam, and Laos [<a href="#rid13">13</a>] (see <a class="local">'Drug resistance'</a> below). In addition, mefloquine does not prevent the development of the hypnozoites of <em>P. vivax</em> or <em>P. ovale </em>malaria. For those with extended exposure to areas with high rates of infection due to these species, presumptive antirelapse therapy with <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> may be necessary to prevent relapse. (See <a class="local">'Drug mechanisms'</a> below and <a class="local">'Primaquine'</a> below and <a class="local">'Tafenoquine'</a> below.)</p><p><a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">Mefloquine</a> is administered weekly beginning at least two weeks prior to exposure, during exposure, and for four weeks following exposure. Dosing is outlined in the tables  (<a class="graphic graphic_table graphicRef75761" href="/z/d/graphic/75761.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef54777" href="/z/d/graphic/54777.html" rel="external">table 2</a>). Some travelers experience adverse effects from mefloquine; most are mild, self-limited, and do not require discontinuation of the drug. The most frequent adverse effects are gastrointestinal upset, lightheadedness, headache, difficulty concentrating, mood swings, and strange dreams [<a href="#rid41">41</a>]. About 5 percent of travelers experience disabling neuropsychiatric adverse effects requiring discontinuation of the drug. These include anxiety, depression, nightmares, paranoid ideation, and dizziness. About 1 in 10,000 travelers experience severe neuropsychiatric reactions such as seizures and psychosis. Adverse effects appear to be more common among women and less frequent among children [<a href="#rid73">73</a>]. Most adverse effects requiring mefloquine discontinuation occur within the first three doses. Therefore, some favor starting mefloquine four weeks prior to travel to determine drug tolerance.</p><p>Contraindications to <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> include known hypersensitivity to the drug, a history of seizures, or major psychiatric disorder and a recent history of depression or anxiety. Development of psychiatric symptoms (such as depression, anxiety, restlessness, or confusion) while taking mefloquine should be viewed as a possible prelude to other events; in such circumstances, it is advisable to stop the drug immediately and switch to a different prophylaxis agent. Mefloquine has also been associated with sinus bradycardia and QT interval prolongation; therefore, it should be used with caution in patients with cardiac conduction disorders or those taking antiarrhythmic medications.</p><p>For pregnant patients who cannot avoid travel to areas with chloroquine-resistant <em>P. falciparum</em>, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> may be safely administered during all trimesters [<a href="#rid74">74</a>]. (See <a class="local">'Pregnant patients'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h4">Primaquine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> has activity against many stages of the malaria parasite including hypnozoites, tissue schizonts, gametocytes, and asexual blood stages of <em>P. vivax</em>  (<a class="graphic graphic_figure graphicRef70176" href="/z/d/graphic/70176.html" rel="external">figure 4</a>) [<a href="#rid21">21,75</a>] (see  <a class="medical medical_review" href="/z/d/html/5703.html" rel="external">"Pathogenesis of malaria", section on 'Life cycle'</a>). It is useful for preventing relapses from the hypnozoite forms of <em>P. vivax</em> and <em>P. ovale</em>; it also has activity against <em>P. falciparum</em> gametocytes [<a href="#rid59">59</a>]. The efficacy of primaquine for protection against <em>P. falciparum</em> and <em>P. vivax </em>is 74 to 95 percent and 85 to 92 percent, respectively [<a href="#rid59">59,61,76-78</a>]. Primaquine has poorer efficacy against <em>P. falciparum</em> and therefore should not be used as primary prophylaxis in areas with <em>P. falciparum</em>. </p><p><a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> may be used either as presumptive antirelapse therapy (PART; the term terminal prophylaxis has also been used in the literature) (see <a class="local">'Relapse prevention'</a> below) or as primary prophylaxis. Primaquine primary prophylaxis is appropriate for travelers to regions where the principal endemic species is <em>P. vivax</em> (such as Mexico and Central America)  (<a class="graphic graphic_figure graphicRef72797" href="/z/d/graphic/72797.html" rel="external">figure 2</a>). Primaquine is administered daily beginning one to two days prior to exposure, once daily during exposure, and daily for seven days following exposure. Dosing is outlined in the tables  (<a class="graphic graphic_table graphicRef75761" href="/z/d/graphic/75761.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef54777" href="/z/d/graphic/54777.html" rel="external">table 2</a>) [<a href="#rid76">76</a>].</p><p><a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> can cause hemolytic anemia in those with G6PD deficiency. Therefore, a G6PD level must be determined prior to the first administration of this drug, and patients should receive primaquine only if G6PD deficiency has been excluded. Primaquine may also cause gastrointestinal upset that can be minimized if taken with food. Primaquine is contraindicated in pregnancy and women breastfeeding infants with unknown G6PD status.</p><p class="headingAnchor" id="H172075680"><span class="h4">Tafenoquine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">Tafenoquine</a> is an 8-aminoquinoline drug related to <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a>. It is active against all stages of <em>Plasmodium</em> species, including hypnozoites (dormant liver stage) of the <em>P. vivax</em> (and by extrapolation, <em>P. ovale</em>) parasite responsible for relapses of malaria. Its long half-life (approximately two weeks) allows for fewer doses than primaquine. In the single available comparative trial, it had similar prophylactic outcomes as <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> [<a href="#rid79">79-81</a>].</p><p><a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">Tafenoquine</a> was approved by the United States Food and Drug Administration in 2018 for prevention of infection due to all species of malaria in individuals ≥18 years of age, and for radical cure <em>P. vivax</em> infection in individuals ≥16 years of age. Use for prophylaxis is limited to six months duration.</p><p>When used for malaria prophylaxis, the regimen consists of 200 mg daily (two 100 mg tablets) by mouth beginning three days prior to exposure, weekly during exposure (starting seven days after last loading dose), and once in the week following exposure [<a href="#rid82">82</a>]. The dosing regimen may be appealing for those with shorter trips or seeking last-minute travel advice. <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">Tafenoquine</a> should be taken with food to prevent gastrointestinal upset.</p><p><a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">Tafenoquine</a> can cause severe hemolytic anemia in those with G6PD deficiency. Therefore, a quantitative G6PD test must be done to rule out G6PD deficiency prior to the first administration of the drug. Note that qualitative G6PD testing can miss those with moderate deficiency, and is not sufficient to establish normal G6PD activity. Tafenoquine is contraindicated in pregnancy since the G6PD status of the fetus is unknown. Tafenoquine should not be used in women breastfeeding infants with unknown or deficient G6PD levels. The most common side effects include dizziness, nausea, vomiting, headache, and nonclinically significant decreases in hemoglobin. Use of tafenoquine is not recommended in patients with a history of psychiatric disorders [<a href="#rid83">83,84</a>]. Vortex keratopathy not affecting visual acuity is also associated with use of tafenoquine and in studies of use up to six months has been observed to be reversible upon discontinuation of the medication. </p><p class="headingAnchor" id="H16"><span class="h3">Relapse prevention</span><span class="headingEndMark"> — </span>Late-onset or relapsed disease due to reactivation of hypnozoites can occur up to many months after initial infection with <em>P. vivax </em>and <em>P. ovale</em>. Hypnozoites are a quiescent stage in the liver that exist only in the setting of <em>P. vivax</em> and <em>P. ovale</em> infection. Hepatic stages cause no fever symptoms, and one does not need to have had a primary clinical episode of malaria in order to have a relapse.</p><p>Use of <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> for presumptive antirelapse therapy (PART) is appropriate for travelers to regions where there is substantial transmission of <em>P. vivax</em> or <em>P. ovale</em>, even if <em>P. falciparum</em> is the predominant endemic species [<a href="#rid41">41,85</a>]. If primaquine or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> is used for prophylaxis, there is no need for PART. </p><p>PART is especially appropriate for travelers with prolonged stays (eg, several months or more) where <em>P. vivax</em> or <em>P. ovale</em> are present [<a href="#rid41">41</a>]. In addition to taking an agent for prophylaxis with activity against blood-stage parasites prior to, during, and following exposure (such as <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a>, <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a>, or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>), <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> is added for activity against liver hypnozoites, which can cause disease after completion of the primary chemoprophylaxis regimen  (<a class="graphic graphic_figure graphicRef70176" href="/z/d/graphic/70176.html" rel="external">figure 4</a>). If primaquine or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> is used for primary chemoprophylaxis, PART is not needed.</p><p>Following departure from an endemic area, <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> may be administered for relapse prevention, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> should be administered for 14 days together with the remainder of the primary prophylaxis regimen. If the primary prophylaxis regimen has already been completed, a course of primaquine is still beneficial for prevention of relapse  (<a class="graphic graphic_table graphicRef75761" href="/z/d/graphic/75761.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef54777" href="/z/d/graphic/54777.html" rel="external">table 2</a>). </p><p></p><p>Issues related to relapse prevention are discussed in further detail separately. (See  <a class="medical medical_review" href="/z/d/html/5706.html" rel="external">"Non-falciparum malaria: P. vivax, P. ovale, and P. malariae", section on 'Preventing relapse'</a>.)</p><p class="headingAnchor" id="H3633959554"><span class="h3">Special populations</span></p><p class="headingAnchor" id="H17"><span class="h4">Pregnant patients</span><span class="headingEndMark"> — </span>Malaria can be a life-threatening infection for both mother and fetus [<a href="#rid26">26,86</a>]. Risk of stillbirth, spontaneous abortion, and other adverse pregnancy outcomes is increased in the setting of malaria, and pregnant patients should be advised to defer travel until after delivery whenever feasible. (See  <a class="medical medical_review" href="/z/d/html/4795.html" rel="external">"Malaria in pregnancy: Epidemiology, clinical manifestations, diagnosis, and outcome"</a>.)</p><p>For pregnant patients who cannot defer travel to regions where chloroquine-sensitive malaria is present, mosquito avoidance measures should be used in conjunction with chemoprophylaxis with <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> [<a href="#rid13">13,87</a>]. <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">Mefloquine</a> is also acceptable.</p><p>For pregnant patients who cannot defer travel to regions where chloroquine-resistant malaria is present, mosquito avoidance measures should be used in conjunction with chemoprophylaxis using <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> [<a href="#rid88">88-90</a>].</p><p><a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">Mefloquine</a> may be safely administered during all trimesters [<a href="#rid88">88,91,92</a>]. Safety data on <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a> in pregnancy are limited, so this agent should be avoided in pregnancy. There is some concern that <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> administered during pregnancy has potential adverse effects to the fetus including dysplasia, inhibition of bone growth, and dental discoloration. Its use in pregnancy is allowed in some countries up to the first 15 weeks in pregnancy; in others its use is contraindicated in pregnancy. <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> and <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> should not be administered during pregnancy given the possibility of fetal G6PD deficiency.</p><p>Issues related to mosquito avoidance are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4085.html" rel="external">"Prevention of arthropod and insect bites: Repellents and other measures"</a>.)</p><p class="headingAnchor" id="H16818608"><span class="h4">Children</span><span class="headingEndMark"> — </span>All children traveling to malaria-endemic areas should take antimalarial prophylaxis. <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> and <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> are options for use in infants and children of all ages and weights  (<a class="graphic graphic_table graphicRef54777" href="/z/d/graphic/54777.html" rel="external">table 2</a>). <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">Atovaquone-proguanil</a> may be administered to individuals ≥5 kg; <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> may be administered to individuals ≥8 years  (<a class="graphic graphic_table graphicRef54777" href="/z/d/graphic/54777.html" rel="external">table 2</a>). Antimalarial prophylaxis medications are only available in pill form; for children unable to swallow pills, the pills should be crushed and mixed with food or drink.</p><p class="headingAnchor" id="H62154113"><span class="h3">Drug mechanisms</span><span class="headingEndMark"> — </span>There are three major categories of drugs for prevention of malaria  (<a class="graphic graphic_figure graphicRef70176" href="/z/d/graphic/70176.html" rel="external">figure 4</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Tissue (hepatic) schizonticides – These drugs target the liver stages of the parasite, the active tissue schizonts. <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">Atovaquone-proguanil</a> and <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> have proven activity against liver stages of <em>P. falciparum</em>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypnozoiticide – Hypnozoites are a quiescent stage in the liver that exist only in the setting of <em>P. vivax</em> and <em>P. ovale </em>infection. This liver stage does not cause clinical symptoms, but, with reactivation and release into the circulation, late-onset or relapsed disease can occur up to many months after initial infection. <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> and <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> are active against the hypnozoites of <em>P. vivax</em> and <em>P. ovale</em>. (See <a class="local">'Relapse prevention'</a> above and <a class="local">'Primaquine'</a> above and <a class="local">'Tafenoquine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood schizonticides – This class of drugs targets the asexual blood stages of the parasite; it includes <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a>, <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a>, and to some degree, <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a>. Because the first three agents act on blood parasites following release from the initial maturation phase in the liver, these drugs must be continued for four weeks following exposure to eradicate parasites released from the liver.</p><p></p><p><a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> has schizonticidal activity against the tissue stages of all species and the blood stages of the non-falciparum species but lacks sufficient blood schizonticidal activity against <em>P. falciparum</em> and therefore should not be used to treat or prevent this illness. Since <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a>, primaquine, and <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> act as both blood and tissue schizonticides, they interfere with development of actively replicating parasites in the liver and so can be discontinued one week (single post-trip dose for tafenoquine) after the end of exposure. On the basis of small human challenge studies, some experts recommend discontinuing these drugs three days after exposure [<a href="#rid75">75,93</a>]. However, cases of acute malaria have been reported after abbreviated courses of atovaquone-proguanil chemoprophylaxis. A larger study is needed to determine whether an abbreviated course is adequate.</p><p class="headingAnchor" id="H2341268029"><span class="h3">Drug resistance</span><span class="headingEndMark"> — </span>Antimalarial selection should include the considerations of regions with malarial drug resistance  (<a class="graphic graphic_figure graphicRef103385" href="/z/d/graphic/103385.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef72797" href="/z/d/graphic/72797.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef142995" href="/z/d/graphic/142995.html" rel="external">figure 3</a>) [<a href="#rid94">94-97</a>]. Individual itineraries should be reviewed together with the most recent guidelines and advisories [<a href="#rid12">12,13</a>].</p><p>Resistance of <em>P. falciparum</em> to <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> is widespread; regions with chloroquine-resistant and chloroquine-sensitive malaria are summarized below:</p><p class="bulletIndent1"><span class="glyph">●</span>Chloroquine-resistant <em>P. falciparum</em> is widespread in endemic areas of Africa, Asia, and Oceania.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chloroquine-sensitive <em>P. falciparum</em> exists in the Caribbean and in Central America west and north of the Panama Canal  (<a class="graphic graphic_figure graphicRef103385" href="/z/d/graphic/103385.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef72797" href="/z/d/graphic/72797.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef142995" href="/z/d/graphic/142995.html" rel="external">figure 3</a>) [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>P. falciparum</em> strains resistant to <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> and <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> are rare but are prevalent in the regions of Thailand bordering Myanmar (Burma) and Cambodia (eg, eastern provinces of Myanmar and western provinces of Cambodia) and in parts of China, Laos, and Vietnam [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chloroquine-resistant <em>P. vivax</em> is widespread in Indonesian Papua and Papua New Guinea [<a href="#rid13">13,98</a>].</p><p></p><p class="headingAnchor" id="H18"><span class="h3">Drug interactions</span><span class="headingEndMark"> — </span>Prior to prescribing antimalarial medication, the traveler's medication history should be reviewed in detail with consideration for potential drug-drug interactions. Some relatively common drugs with important interactions include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a> – <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a>/proguanil and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> may diminish metabolism of warfarin. Coagulation parameters should be monitored closely if these drugs are used together, and the warfarin dosing may need to be reduced [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiarrhythmic agents – These drugs should be used with caution in the setting of <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> administration, which has been associated with sinus bradycardia and QT interval prolongation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppressive medications – <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> may increase <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> levels, and both <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> may increase levels of cyclosporine and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid100">100</a>]. <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">Atovaquone-proguanil</a> does not have known interactions with these medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiretroviral agents – Drug-drug interactions are common with some antiretroviral agents. Information about these interactions should be reviewed prior to prescribing antimalarial medications [<a href="#rid101">101</a>]. </p><p></p><p class="headingAnchor" id="H3640281650"><span class="h2">Monoclonal antibodies</span><span class="headingEndMark"> — </span>Issues related to monoclonal antibodies for malaria prevention are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/5702.html" rel="external">"Malaria: Epidemiology, prevention, and control", section on 'Monoclonal antibodies'</a>.)</p><p class="headingAnchor" id="H4241185990"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113035.html" rel="external">"Society guideline links: Malaria"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115404.html" rel="external">"Society guideline links: Travel medicine"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15744.html" rel="external">"Patient education: Vaccines for travel (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/85721.html" rel="external">"Patient education: Malaria (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/7960.html" rel="external">"Patient education: General travel advice (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Malaria is an important cause of fever and serious illness in returned travelers. Approximately 2000 cases of imported malaria are reported annually to the United States Centers for Disease Control and Prevention (CDC); more than half of these are due to <em>Plasmodium falciparum</em>. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk assessment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Destination</strong> – Risk assessment for malaria requires detailed review of the planned itinerary together with the most recent CDC guidelines and advisories. A summary of areas with malaria transmission and prophylaxis by country is available on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fyellowbook%2F2020%2Fpreparing-international-travelers%2Fyellow-fever-vaccine-and-malaria-prophylaxis-information-by-country&amp;token=jj2UHfLp0WCDP%2BPnnDHYtKwUU4imTsGBlINAeMEWO%2B5%2F25q8IO5C2rkXk78xTtwPruzB3AB33QirmoFzXo3YJh7xCLA8Y2%2F97HmNzKzNqc7FXaWJNCC0wvp6P3MCpBNk4UsIVhZ2x5Tkbcp3jT7AvHUUUCWgruPdU6dafXbr10c%3D&amp;TOPIC_ID=5722" target="_blank">CDC website</a>. (See <a class="local">'Destination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Type of traveler</strong> – High-risk groups also include travelers born in regions with endemic malaria who relocate outside the endemic area but subsequently return to visit friends and relatives, pregnant patients, and military personnel. (See <a class="local">'Type of traveler'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling</strong> – Travelers to malarious areas should be counseled regarding mosquito bite prevention and adherence to antimalarial chemoprophylaxis if indicated. However, travelers must also understand that no chemoprophylaxis regimen guarantees complete protection; fever during or after travel is a medical emergency requiring urgent medical attention. (See <a class="local">'Counseling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mosquito bite prevention</strong> – Travelers should receive instructions regarding methods to prevent bites from <em>Anopheles</em> mosquitoes, including avoiding outdoor exposure between dusk and dawn, wearing clothing that reduces the amount of exposed skin, wearing insect repellant (eg, N,N-diethyl-meta-toluamide [DEET], picaridin, ethyl butylacetylaminopropionate [IR3535] or oil of lemon eucalyptus), staying in well-screened or air-conditioned rooms, and sleeping within bed nets treated with insecticide (eg, <a class="drug drug_general" data-topicid="9759" href="/z/d/drug information/9759.html" rel="external">permethrin</a>). (See <a class="local">'Mosquito bite prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemoprophylaxis</strong> – We recommend chemoprophylaxis for patients at risk of malaria infection because of travel to destinations with malaria transmission (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Because of variation in malaria transmission and antimalarial drug resistance, individual itineraries should be reviewed together with the most recent CDC guidelines and advisories  (<a class="graphic graphic_table graphicRef75761" href="/z/d/graphic/75761.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef54777" href="/z/d/graphic/54777.html" rel="external">table 2</a>). (See <a class="local">'Chemoprophylaxis'</a> above and <a class="local">'Suggested approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse prevention</strong> – Late-onset or relapsed disease due to reactivation of <em>Plasmodium vivax</em> or <em>Plasmodium ovale</em> hypnozoites can occur up to many months after initial infection. Use of <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> for presumptive antirelapse therapy is appropriate for travelers to regions where there is substantial transmission of <em>P. vivax</em> or <em>P. ovale</em>, even if <em>P. falciparum</em> is the predominant endemic species. (See <a class="local">'Relapse prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnant patients</strong> – Pregnant patients traveling to malarious areas are increased risk for life-threatening infection and adverse outcomes for both mother and fetus. Pregnant patients should be advised to defer travel to malarious areas until after delivery whenever feasible. Chemoprophylaxis in the setting of pregnancy is discussed above. (See <a class="local">'Pregnant patients'</a> above.)</p><p></p><p class="headingAnchor" id="H1529599452"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ellen O Boundy, ScD, MS, RN, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44:1560.</a></li><li><a class="nounderline abstract_t">Angelo KM, Libman M, Caumes E, et al. Malaria after international travel: a GeoSentinel analysis, 2003-2016. Malar J 2017; 16:293.</a></li><li><a class="nounderline abstract_t">Mace KE, Lucchi NW, Tan KR. Malaria Surveillance - United States, 2017. MMWR Surveill Summ 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Hwang J, Cullen KA, Kachur SP, et al. Severe morbidity and mortality risk from malaria in the United States, 1985-2011. Open Forum Infect Dis 2014; 1:ofu034.</a></li><li><a class="nounderline abstract_t">Taylor CA, Blau DM, Diangelo CR, et al. Malaria diagnosed by autopsy in a young traveler returning from Uganda: limitations of surveillance. J Travel Med 2013; 20:47.</a></li><li><a class="nounderline abstract_t">Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008; 46:165.</a></li><li><a class="nounderline abstract_t">Kochar DK, Saxena V, Singh N, et al. Plasmodium vivax malaria. Emerg Infect Dis 2005; 11:132.</a></li><li><a class="nounderline abstract_t">Landman KZ, Tan KR, Arguin PM. Adherence to malaria prophylaxis among Peace Corps Volunteers in the Africa region, 2013. Travel Med Infect Dis 2015; 13:61.</a></li><li><a class="nounderline abstract_t">Svenson JE, MacLean JD, Gyorkos TW, Keystone J. Imported malaria. Clinical presentation and examination of symptomatic travelers. Arch Intern Med 1995; 155:861.</a></li><li><a class="nounderline abstract_t">Krause G, Schöneberg I, Altmann D, Stark K. Chemoprophylaxis and malaria death rates. Emerg Infect Dis 2006; 12:447.</a></li><li><a class="nounderline abstract_t">Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med 2008; 359:603.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Travelers' Health. http://wwwnc.cdc.gov/travel/ (Accessed on June 30, 2015).</li><li class="breakAll">Centers for Disease Control and Prevention. Health Information for International Travel 2020: The Yellow Book. https://wwwnc.cdc.gov/travel/page/yellowbook-home (Accessed on October 29, 2020).</li><li class="breakAll">https://www.who.int/news-room/fact-sheets/detail/malaria (Accessed on April 28, 2021).</li><li><a class="nounderline abstract_t">Leder K, Tong S, Weld L, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 2006; 43:1185.</a></li><li><a class="nounderline abstract_t">Fenner L, Weber R, Steffen R, Schlagenhauf P. Imported infectious disease and purpose of travel, Switzerland. Emerg Infect Dis 2007; 13:217.</a></li><li><a class="nounderline abstract_t">Askling HH, Nilsson J, Tegnell A, et al. Malaria risk in travelers. Emerg Infect Dis 2005; 11:436.</a></li><li><a class="nounderline abstract_t">Bacaner N, Stauffer B, Boulware DR, et al. Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA 2004; 291:2856.</a></li><li><a class="nounderline abstract_t">Ciminera P, Brundage J. Malaria in U.S. military forces: a description of deployment exposures from 2003 through 2005. Am J Trop Med Hyg 2007; 76:275.</a></li><li><a class="nounderline abstract_t">Newman RD, Parise ME, Barber AM, Steketee RW. Malaria-related deaths among U.S. travelers, 1963-2001. Ann Intern Med 2004; 141:547.</a></li><li><a class="nounderline abstract_t">Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria--implications for chemoprophylaxis in travelers. N Engl J Med 2003; 349:1510.</a></li><li><a class="nounderline abstract_t">D'Ortenzio E, Godineau N, Fontanet A, et al. Prolonged Plasmodium falciparum infection in immigrants, Paris. Emerg Infect Dis 2008; 14:323.</a></li><li><a class="nounderline abstract_t">Causer LM, Filler S, Wilson M, et al. Evaluation of reported malaria chemoprophylactic failure among travelers in a US University Exchange Program, 2002. Clin Infect Dis 2004; 39:1583.</a></li><li><a class="nounderline abstract_t">Reyburn H, Mbatia R, Drakeley C, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 2004; 329:1212.</a></li><li><a class="nounderline abstract_t">Keystone JS. The sound of hoof beats does not always mean that it is a zebra. Clin Infect Dis 2004; 39:1589.</a></li><li><a class="nounderline abstract_t">Roggelin L, Cramer JP. Malaria prevention in the pregnant traveller: a review. Travel Med Infect Dis 2014; 12:229.</a></li><li><a class="nounderline abstract_t">Lupi E, Hatz C, Schlagenhauf P. The efficacy of repellents against Aedes, Anopheles, Culex and Ixodes spp. - a literature review. Travel Med Infect Dis 2013; 11:374.</a></li><li><a class="nounderline abstract_t">Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002; 347:13.</a></li><li><a class="nounderline abstract_t">Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2004; :CD000363.</a></li><li><a class="nounderline abstract_t">Frances SP, Waterson DG, Beebe NW, Cooper RD. Field evaluation of repellent formulations containing deet and picaridin against mosquitoes in Northern Territory, Australia. J Med Entomol 2004; 41:414.</a></li><li><a class="nounderline abstract_t">Kimani EW, Vulule JM, Kuria IW, Mugisha F. Use of insecticide-treated clothes for personal protection against malaria: a community trial. Malar J 2006; 5:63.</a></li><li><a class="nounderline abstract_t">Faulde MK, Uedelhoven WM, Robbins RG. Contact toxicity and residual activity of different permethrin-based fabric impregnation methods for Aedes aegypti (Diptera: Culicidae), Ixodes ricinus (Acari: Ixodidae), and Lepisma saccharina (Thysanura: Lepismatidae). J Med Entomol 2003; 40:935.</a></li><li><a class="nounderline abstract_t">Fradin MS. Mosquitoes and mosquito repellents: a clinician's guide. Ann Intern Med 1998; 128:931.</a></li><li><a class="nounderline abstract_t">van Riemsdijk MM, Sturkenboom MC, Ditters JM, et al. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther 2002; 72:294.</a></li><li><a class="nounderline abstract_t">Steinhardt LC, Magill AJ, Arguin PM. Review: Malaria chemoprophylaxis for travelers to Latin America. Am J Trop Med Hyg 2011; 85:1015.</a></li><li><a class="nounderline abstract_t">Tan KR, Henderson SJ, Williamson J, et al. Long term health outcomes among Returned Peace Corps Volunteers after malaria prophylaxis, 1995-2014. Travel Med Infect Dis 2017; 17:50.</a></li><li><a class="nounderline abstract_t">Saunders DL, Garges E, Manning JE, et al. Safety, Tolerability, and Compliance with Long-Term Antimalarial Chemoprophylaxis in American Soldiers in Afghanistan. Am J Trop Med Hyg 2015; 93:584.</a></li><li><a class="nounderline abstract_t">Chen LH, Keystone JS. New strategies for the prevention of malaria in travelers. Infect Dis Clin North Am 2005; 19:185.</a></li><li><a class="nounderline abstract_t">Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa - a six country study. PLoS One 2008; 3:e2132.</a></li><li><a class="nounderline abstract_t">Dondorp AM, Newton PN, Mayxay M, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 2004; 9:1241.</a></li><li><a class="nounderline abstract_t">Chen LH, Wilson ME, Schlagenhauf P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 2007; 297:2251.</a></li><li><a class="nounderline abstract_t">Boggild AK, Parise ME, Lewis LS, Kain KC. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg 2007; 76:208.</a></li><li><a class="nounderline abstract_t">Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33:1015.</a></li><li><a class="nounderline abstract_t">Chulay JD. Challenges in the development of antimalarial drugs with causal prophylactic activity. Trans R Soc Trop Med Hyg 1998; 92:577.</a></li><li><a class="nounderline abstract_t">Shapiro TA, Ranasinha CD, Kumar N, Barditch-Crovo P. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg 1999; 60:831.</a></li><li><a class="nounderline abstract_t">Berman JD, Nielsen R, Chulay JD, et al. Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. Trans R Soc Trop Med Hyg 2001; 95:429.</a></li><li><a class="nounderline abstract_t">Savelkoel J, Binnendijk KH, Spijker R, et al. Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: A systematic review. Travel Med Infect Dis 2018; 21:3.</a></li><li><a class="nounderline abstract_t">Høgh B, Clarke PD, Camus D, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. Lancet 2000; 356:1888.</a></li><li><a class="nounderline abstract_t">Lell B, Luckner D, Ndjavé M, et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351:709.</a></li><li><a class="nounderline abstract_t">Shanks GD, Gordon DM, Klotz FW, et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998; 27:494.</a></li><li><a class="nounderline abstract_t">Sukwa TY, Mulenga M, Chisdaka N, et al. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999; 60:521.</a></li><li><a class="nounderline abstract_t">van der Berg JD, Duvenage CS, Roskell NS, Scott TR. Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum malaria in South Africa. Clin Ther 1999; 21:741.</a></li><li><a class="nounderline abstract_t">Ling J, Baird JK, Fryauff DJ, et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 2002; 35:825.</a></li><li><a class="nounderline abstract_t">Camus D, Djossou F, Schilthuis HJ, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Clin Infect Dis 2004; 38:1716.</a></li><li><a class="nounderline abstract_t">McKeage K, Scott L. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria. Drugs 2003; 63:597.</a></li><li><a class="nounderline abstract_t">Salako LA. Toxicity and side-effects of antimalarials in Africa: a critical review. Bull World Health Organ 1984; 62 Suppl:63.</a></li><li><a class="nounderline abstract_t">Appleton B, Wolfe MS, Mishtowt GI. Chloroquine as a malarial suppressive: absence of visual effects. Mil Med 1973; 138:225.</a></li><li><a class="nounderline abstract_t">Pang LW, Limsomwong N, Boudreau EF, Singharaj P. Doxycycline prophylaxis for falciparum malaria. Lancet 1987; 1:1161.</a></li><li><a class="nounderline abstract_t">Soto J, Toledo J, Rodriquez M, et al. Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 129:241.</a></li><li><a class="nounderline abstract_t">Tan KR, Magill AJ, Parise ME, et al. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg 2011; 84:517.</a></li><li><a class="nounderline abstract_t">Weiss WR, Oloo AJ, Johnson A, et al. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 1995; 171:1569.</a></li><li><a class="nounderline abstract_t">Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126:963.</a></li><li><a class="nounderline abstract_t">Andersen SL, Oloo AJ, Gordon DM, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis 1998; 26:146.</a></li><li><a class="nounderline abstract_t">Takafuji ET, Kirkpatrick JW, Miller RN, et al. An efficacy trial of doxycycline chemoprophylaxis against leptospirosis. N Engl J Med 1984; 310:497.</a></li><li><a class="nounderline abstract_t">Olson JG, Bourgeois AL, Fang RC, et al. Prevention of scrub typhus. Prophylactic administration of doxycycline in a randomized double blind trial. Am J Trop Med Hyg 1980; 29:989.</a></li><li><a class="nounderline abstract_t">Wallace MR, Sharp TW, Smoak B, et al. Malaria among United States troops in Somalia. Am J Med 1996; 100:49.</a></li><li><a class="nounderline abstract_t">Frost P, Weinstein GD, Gomez EC. Phototoxic potential of minocycline and doxycycline. Arch Dermatol 1972; 105:681.</a></li><li><a class="nounderline abstract_t">Phillips MA, Kass RB. User Acceptability Patterns for Mefloquine and Doxycycline Malaria Chemoprophylaxis. J Travel Med 1996; 3:40.</a></li><li><a class="nounderline abstract_t">Morris TJ, Davis TP. Doxycycline-induced esophageal ulceration in the U.S. Military service. Mil Med 2000; 165:316.</a></li><li><a class="nounderline abstract_t">Tickell-Painter M, Maayan N, Saunders R, et al. Mefloquine for preventing malaria during travel to endemic areas. Cochrane Database Syst Rev 2017; 10:CD006491.</a></li><li><a class="nounderline abstract_t">Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993; 341:1299.</a></li><li><a class="nounderline abstract_t">Eick-Cost AA, Hu Z, Rohrbeck P, Clark LL. Neuropsychiatric Outcomes After Mefloquine Exposure Among U.S. Military Service Members. Am J Trop Med Hyg 2017; 96:159.</a></li><li><a class="nounderline abstract_t">Schlagenhauf P, Adamcova M, Regep L, et al. Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data. Malar J 2011; 10:292.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Malaria. Update: New Recommendations for Mefloquine Use in Pregnancy www.cdc.gov/malaria/new_info/2011/mefloquine_pregnancy.html (Accessed on June 29, 2015).</li><li><a class="nounderline abstract_t">Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003; 37:1659.</a></li><li><a class="nounderline abstract_t">Hill DR, Baird JK, Parise ME, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006; 75:402.</a></li><li><a class="nounderline abstract_t">Baird JK, Fryauff DJ, Basri H, et al. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 1995; 52:479.</a></li><li><a class="nounderline abstract_t">Schwartz E, Regev-Yochay G. Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline. Clin Infect Dis 1999; 29:1502.</a></li><li><a class="nounderline abstract_t">Dow GS, Liu J, Lin G, et al. Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries. Malar J 2015; 14:473.</a></li><li><a class="nounderline abstract_t">Baird JK. Tafenoquine for travelers' malaria: evidence, rationale and recommendations. J Travel Med 2018; 25.</a></li><li><a class="nounderline abstract_t">Freedman DO. Tafenoquine: integrating a new drug for malaria prophylaxis into travel medicine practice. J Travel Med 2019; 26.</a></li><li><a class="nounderline abstract_t">Haston JC, Hwang J, Tan KR. Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria - United States, 2019. MMWR Morb Mortal Wkly Rep 2019; 68:1062.</a></li><li class="breakAll">Arakoda [package insert]. Washington DC: 60 Degrees Pharmaceuticals; 2018.</li><li class="breakAll">Krintafel [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2018.</li><li><a class="nounderline abstract_t">Galappaththy GN, Omari AA, Tharyan P. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst Rev 2007; :CD004389.</a></li><li><a class="nounderline abstract_t">Lindsay S, Ansell J, Selman C, et al. Effect of pregnancy on exposure to malaria mosquitoes. Lancet 2000; 355:1972.</a></li><li><a class="nounderline abstract_t">Whitty CJ, Edmonds S, Mutabingwa TK. Malaria in pregnancy. BJOG 2005; 112:1189.</a></li><li><a class="nounderline abstract_t">Smoak BL, Writer JV, Keep LW, et al. The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen. J Infect Dis 1997; 176:831.</a></li><li><a class="nounderline abstract_t">Steketee RW, Wirima JJ, Slutsker L, et al. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 1996; 55:50.</a></li><li><a class="nounderline abstract_t">Okeyeh JN, Lege-Oguntoye L, Emembolu JO, Agbo M. Malaria in pregnancy: efficacy of a low dose of mefloquine in an area holoendemic for multi-drug resistant Plasmodium falciparum. Ann Trop Med Parasitol 1996; 90:265.</a></li><li><a class="nounderline abstract_t">Nosten F, ter Kuile F, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 1994; 169:595.</a></li><li><a class="nounderline abstract_t">Vanhauwere B, Maradit H, Kerr L. Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. Am J Trop Med Hyg 1998; 58:17.</a></li><li><a class="nounderline abstract_t">Deye GA, Miller RS, Miller L, et al. Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. Clin Infect Dis 2012; 54:232.</a></li><li><a class="nounderline abstract_t">Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004; 48:4075.</a></li><li><a class="nounderline abstract_t">Talisuna AO, Bloland P, D'Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 2004; 17:235.</a></li><li><a class="nounderline abstract_t">Bloland PB, Ettling M. Making malaria-treatment policy in the face of drug resistance. Ann Trop Med Parasitol 1999; 93:5.</a></li><li><a class="nounderline abstract_t">Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184:770.</a></li><li><a class="nounderline abstract_t">Baird JK, Sustriayu Nalim MF, Basri H, et al. Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg 1996; 90:409.</a></li><li><a class="nounderline abstract_t">Warfarin potentiated by proguanil. BMJ 1991; 303:789.</a></li><li><a class="nounderline abstract_t">Kotton CN, Ryan ET, Fishman JA. Prevention of infection in adult travelers after solid organ transplantation. Am J Transplant 2005; 5:8.</a></li><li class="breakAll">University of Liverpool. HIV Drug Interactions. Interaction Checker. https://www.hiv-druginteractions.org/ (Accessed on April 25, 2022).</li></ol></div><div id="topicVersionRevision">Topic 5722 Version 54.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17516399" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fever in returned travelers: results from the GeoSentinel Surveillance Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28728595" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Malaria after international travel: a GeoSentinel analysis, 2003-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33735166" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Malaria Surveillance - United States, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25734104" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Severe morbidity and mortality risk from malaria in the United States, 1985-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23279231" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Malaria diagnosed by autopsy in a young traveler returning from Uganda: limitations of surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171245" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705338" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Plasmodium vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25534297" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Adherence to malaria prophylaxis among Peace Corps Volunteers in the Africa region, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7717795" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Imported malaria. Clinical presentation and examination of symptomatic travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16704783" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chemoprophylaxis and malaria death rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687641" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical practice. Malaria prevention in short-term travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687641" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical practice. Malaria prevention in short-term travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687641" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical practice. Malaria prevention in short-term travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687641" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical practice. Malaria prevention in short-term travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17029140" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17479882" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Imported infectious disease and purpose of travel, Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15757560" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Malaria risk in travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15199037" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Travel medicine considerations for North American immigrants visiting friends and relatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17297035" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Malaria in U.S. military forces: a description of deployment exposures from 2003 through 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466772" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Malaria-related deaths among U.S. travelers, 1963-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14561793" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Delayed onset of malaria--implications for chemoprophylaxis in travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18258132" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prolonged Plasmodium falciparum infection in immigrants, Paris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15578355" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evaluation of reported malaria chemoprophylactic failure among travelers in a US University Exchange Program, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15542534" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15578356" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The sound of hoof beats does not always mean that it is a zebra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813714" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Malaria prevention in the pregnant traveller: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24201040" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The efficacy of repellents against Aedes, Anopheles, Culex and Ixodes spp. - a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12097535" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparative efficacy of insect repellents against mosquito bites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15106149" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Insecticide-treated bed nets and curtains for preventing malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15185943" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Field evaluation of repellent formulations containing deet and picaridin against mosquitoes in Northern Territory, Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16872529" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Use of insecticide-treated clothes for personal protection against malaria: a community trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14765673" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Contact toxicity and residual activity of different permethrin-based fabric impregnation methods for Aedes aegypti (Diptera: Culicidae), Ixodes ricinus (Acari: Ixodidae), and Lepisma saccharina (Thysanura: Lepismatidae).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9634433" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mosquitoes and mosquito repellents: a clinician's guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12235450" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22144437" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Review: Malaria chemoprophylaxis for travelers to Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28487213" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Long term health outcomes among Returned Peace Corps Volunteers after malaria prophylaxis, 1995-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26123954" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Safety, Tolerability, and Compliance with Long-Term Antimalarial Chemoprophylaxis in American Soldiers in Afghanistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15701554" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : New strategies for the prevention of malaria in travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18461128" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antimalarial drug quality in the most severely malarious parts of Africa - a six country study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598255" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519415" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Controversies and misconceptions in malaria chemoprophylaxis for travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17297027" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11528574" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10326094" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Challenges in the development of antimalarial drugs with causal prophylactic activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10344660" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prophylactic activity of atovaquone against Plasmodium falciparum in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579890" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29242073" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11130385" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9504515" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9770146" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348223" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10363739" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum malaria in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12228819" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15227617" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12656656" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6335683" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Toxicity and side-effects of antimalarials in Africa: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4632929" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Chloroquine as a malarial suppressive: absence of visual effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2883488" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Doxycycline prophylaxis for falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9696733" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460003" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7769294" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9182474" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9455524" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6363930" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : An efficacy trial of doxycycline chemoprophylaxis against leptospirosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7435798" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prevention of scrub typhus. Prophylactic administration of doxycycline in a randomized double blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8579087" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Malaria among United States troops in Somalia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5026677" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Phototoxic potential of minocycline and doxycycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815421" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : User Acceptability Patterns for Mefloquine and Doxycycline Malaria Chemoprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10803009" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Doxycycline-induced esophageal ulceration in the U.S. Military service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29083100" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mefloquine for preventing malaria during travel to endemic areas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8098447" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28077744" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Neuropsychiatric Outcomes After Mefloquine Exposure Among U.S. Military Service Members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21981927" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21981927" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14689349" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Primaquine for prevention of malaria in travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16968913" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611550" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585803" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26610844" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30380095" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Tafenoquine for travelers' malaria: evidence, rationale and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30496585" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Tafenoquine: integrating a new drug for malaria prophylaxis into travel medicine practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31751320" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria - United States, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31751320" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria - United States, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31751320" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria - United States, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253504" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Primaquine for preventing relapses in people with Plasmodium vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10859048" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effect of pregnancy on exposure to malaria mosquitoes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16101595" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Malaria in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9291347" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8702037" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8758140" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Malaria in pregnancy: efficacy of a low dose of mefloquine in an area holoendemic for multi-drug resistant Plasmodium falciparum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8158032" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9452285" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22052893" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15504824" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Chloroquine resistance in Plasmodium vivax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14726463" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : History, dynamics, and public health importance of malaria parasite resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10492667" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Making malaria-treatment policy in the face of drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11517439" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Chloroquine-resistant malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8882190" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Survey of resistance to chloroquine by Plasmodium vivax in Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1932962" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Warfarin potentiated by proguanil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15636606" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Prevention of infection in adult travelers after solid organ transplantation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
